Natco Pharma Q2 Results Review - Strong Growth On Low Base; Weak Q3 Expected: Nirmal Bang

Revenue grew by ~139% YoY, on account of a low base in th Ebitda rt business and ramp up in crop protection business led by calculated total peripheral resistance. India Gi">Original DISCLAIMER Revlimid Nirmal Bang Report 7 Natco Pharma Ltd. lass="summaryFeed_highLightText__NxlGi">Rs 28.5 Ebitda Feed_highLightText__NxlGi">September YoY an class="summaryFeed_highLightText__NxlGi">24 Rs 861 Nat ~10% h YoY a 180% g YoY ghtText__N Revlimid cumulate 44.4% d_highLightText_ Revlimid U.S. Natco Pharma _NxlGi">U.S. Revlimid xlGi">two